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ABSTRACT: 
INTRODUCTION: 
The eye is a target for investigational gene therapy due to the monogenic nature of many 
inherited retinal and optic nerve degenerations (IRD), its accessibility, tight blood-ocular 
barrier, the ability to non-invasively monitor for functional and anatomic outcomes, as 
well as its relative immune privileged state. 
AREAS COVERED: 
Vectors currently used in IRD clinical trials include adeno-associated virus (AAV), small 
single-stranded DNA viruses, and lentivirus, RNA viruses of the retrovirus family. Both 
can transduce non-dividing cells, but AAV are non-integrating, while lentivirus integrate 
into the host cell genome, and have a larger transgene capacity. This review covers 
Leber’s congenital amaurosis, choroideremia, retinitis pigmentosa, Usher syndrome, 
Stargardt disease, Leber’s hereditary optic neuropathy, Achromatopsia, and X-linked 
retinoschisis.  
EXPERT OPINION:  
Despite great potential, gene therapy for IRD raises many questions, including the 
potential for less invasive intravitreal versus subretinal delivery, efficacy, safety, and 
longevity of response, and acceptance of novel study endpoints by patients, clinicians, 
and payers.  Also, ultimate adoption of gene therapy for IRD will require widespread 
genetic screening to identify and diagnose patients based on genotype instead of 
phenotype, as well as new reimbursement models for one-time therapies. 
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Inherited retinal degenerations (IRD) are a rare and heterogenous group of diseases that 
collectively result in progressive retinal degeneration with resultant severe visual 
impairment; over 200 causative mutations have been identified.   The most common 
IRDs include Leber’s congential amaurosis (LCA), choroideremia, retinitis pigmentosa 
(RP), Usher syndrome, Stargardt disease, Leber’s hereditary optic neuropathy (LHON), 
Achromatopsia, and X-linked retinoschisis (XLRS) (1). The blinding nature of these 
conditions and lack of effective treatment highlight the need for therapeutic innovation. 
The fact that the disease-causing genes have been identified, together with their 
monogenic etiology facilitates the potential for gene therapy.  Furthermore, IRDs also 
attracted interest because both the United States Food and Drug Administration (FDA) 
and European Medicines Agency (EMA) have incentivized development of therapies for 
rare diseases.  In the US, the Orphan Drug Act of 1983 defined orphan diseases as those 
that affected fewer than 200,000 Americans.  The Orphan Drug Act provided sponsors 
with 7 years of exclusivity, tax credits to defray the cost of development, waived FDA 
fees, and provided protocol assistance. The EMA provided similar incentives.  
 
1.2 Introduction to viral vectors 
For a disease to be a good candidate for treatment using gene therapy, several factors 
need to be fulfilled: (i) Substantial disease burden, and favorable risk/benefit ratio 
compared to alternative therapy; (ii) The relevant gene/locus has been identified, and 
there is sufficient knowledge of the disease process; (iii) The appropriate target cell(s) 
can be targeted with a gene delivery method; (iv) Phenotype improvement is attained 
with low expression levels of the gene, and its overexpression is not associated with 
toxicity. Recessive single gene disorders are the most amenable to be treated by gene 
therapy, because the mutations causing the disease generally lead to loss-of-function of 
the gene product and therefore, total absence or near absence of functional protein. Gene 
replacement therapy in these cases can correct the lost function by delivery of the normal 
gene. Furthermore, in some instances restoring a small percentage of the normal level of 
the gene product is sufficient to revert the phenotype. The majority of gene therapies to 
treat inherited ocular diseases target autosomal recessive diseases. For example, LCA, 
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type 2, mediated by mutations in the RPE65 gene is a recessive monogenic disorder in 
which gene-based therapy corrects the lost function. In contrast, gain-of-function 
mutations produce dominant phenotypes. These diseases may be less amenable to be 
treated by gene therapy, as one gene copy expresses an abnormal product that has to be 
suppressed, while the other expresses a protein that functions normally (2).  
Consequently, developing a gene therapy for autosomal dominant RP has been more 
challenging.  
 
A variety of viral and non-viral gene delivery methods have been developed over the past 
couple of decades. Choosing one delivery method over another is influenced by the tissue 
to be targeted, the cloning capacity of the vector (which determines the size of the 
expression cassette that can be accommodated in the genome of the virus), and safety 
concerns (inflammatory responses, and possibility of genotoxicity/insertional 
oncogenesis). Adeno-associated virus (AAV) and lentivirus vectors have been used in the 
treatment of retinal inherited diseases. Adeno-associated viruses are small, single-
stranded DNA viruses of the parvovirus family (3). AAV vectors transduce quiescent 
tissues, and their genome is mainly maintained as extrachromosomal monomeric and 
concatemeric circles (4). Over 100 different AAV serotypes have been described, each of 
them displaying enhanced tropism for a specific set of tissues. To date, AAV is the most 
common viral vector utilized in retinal genetic therapy. AAV serotypes 2, 5, and 7–9 are 
capable of transducing photoreceptors, while virtually every AAV serotype is capable of 
infecting the retinal pigment epithelium (RPE) (5). Multiple features make it an excellent 
vector choice for these diseases, including the non-integrating nature, low inflammatory 
potential, low immunogenicity, low retinal toxicity at appropriate doses, non-pathogenic 
nature, ability to transduce non-dividing cells, and excellent track record of safety in 
human trials (6-8). AAV vectors do have limitations, which include having a restricted 
transgene capacity (4.5-5.0 kb) and the risk of being rapidly eliminated by the humoral 
immune response in patients who have previously been exposed to the virus (7). 
However, the risk for immunogenicity with AAV vectors is low when targeting relatively 
immune-privileged tissues such as the retina (8). Transduction efficiency using AAV is 
hindered by the requirement of converting the single-stranded DNA genome to double-
stranded DNA, a step that typically takes weeks. To overcome this limitation, 
investigators have developed self-complementary AAV vectors (scAAV), which 
overcome the need for dsDNA conversion by packaging a dimeric inverted repeat 
genome that folds into double stranded DNA (9-10). The caveat to this approach is that 
the size of the expression cassette has to be reduced by half, which is a constraint to the 
already limited cloning capacity of AAV. 
 
Lentiviruses are RNA viruses of the retrovirus family. Commonly used lentiviral vectors 
derive from the human immunodeficiency virus 1 (HIV1) or the equine infectious anemia 
virus (EIAV) (11). Lentivirus vectors efficiently integrate their genome into the host cell 
genome, and do not require cell division for integration (12). Additionally, lentiviruses 
are able to transduce both dividing and non-dividing cells. An added attractive feature is 
the cloning capacity, up to 10 kb (13). Lentiviruses have recently become a popular 
choice because they have improved safety features relative to gamma-retroviruses, as the 
vector genome does not preferentially integrate in the proximity of oncogenes (14). 
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1.3 Methods of introducing viral vectors to the eye  
The eye provides an excellent model for investigating gene therapy because the ocular 
relative immune-privilege limits an immune response to the implanted genetic material 
and the tight blood-ocular barrier limits the systemic dissemination of the introduced 
genetic material. Additional advantages include ease of accessibility for delivery of the 
genetic material directly to the target cells of interest, the non-invasive ability to monitor 
for disease progression and response to therapy, and use of the contralateral eye as an in 
vivo control (15).    
 
Vector delivery to the target retinal tissue involves two potential methods. The most 
commonly investigated method involves pars plana vitrectomy (PPV) followed by 
retinotomy and injection of the viral vector with genetic material into the subretinal space 
(Figure 1). This more invasive method creates a temporary retinal detachment, but allows 
for direct delivery to the cells of interest. The virus then “infects” the RPE cells or 
photoreceptors, causing the host cells own translational machinery to express the protein. 
Alternatively, injection of the vector into the vitreous cavity has been attempted, and 
although this method may be less invasive and potentially have fewer procedure-related 
complications, the penetration of viral vector to the target tissue is perceived to be 
inferior to that of subretinal injections (16) (Figure 2). Additionally, animal models have 
demonstrated an induced humoral immune response to intravitreally delivered vectors 
that was not observed with subretinally delivered vectors (17). This review will explore 
the current state of genetic replacement therapy research and clinical trials as it pertains 
to a subset of IRDs with specific genetic mutations including Leber’s congential 
amaurosis (LCA), choroideremia, X-linked and autosomal recessive retinitis pigmentosa 
(RP), Usher syndrome, Stargardt’s disease, Leber’s hereditary optic neuropathy (LHON), 
Achromatopsia, and X-linked retinoschisis (XLRS) (Table 1 and 2).  
 
2.1 Gene therapies for Leber’s Congenital Amaurosis: 
Leber's congenital amaurosis (LCA) is a heterogenous group of infantile-onset, retinal 
dystrophy caused by a variety of genetic mutations (18-19). It is a rare, visually 
devastating disease with an estimated prevalence of 1 in 50,000-100,000 resulting in 
nystagmus and severely decreased visual acuity (VA) in early infancy; complete 
blindness typically ensues by the third to fourth decade of life (20). One of the pathologic 
genetic mutations of interest involves the RPE65 gene encoding retinoid 
isomerohydrolase, a 65-kD protein expressed in the RPE, which plays a key role in the 
visual cycle. When light strikes rhodopsin (composed of the protein opsin bound to the 
chromophore 11-cis-retinal) in the rod outer segments, 11-cis-retinal is converted to its 
trans isomer.  This, in turn, activates the opsin and initiates a signal transduction cascade, 
closing a cyclic GMP-gated cation channel, and hyperpolarizing the photoreceptor cell. 
In the visual cycle, 11-cis retinal must ultimately be converted back from its trans isomer, 
via a series of enzymes, including Lecithin Retinol Acyltransferase (LRAT) and retinoid 
isomerohydrolase (encoded by the RPE65 gene), both of which are located in the RPE 
(21-24). Deficiency in either of these enzymes leads to early age onset progressive 
degeneration of rod photoreceptors and ultimately results in irreversible loss of cone-
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mediated vision, a degenerative process that may be mitigated by early initiation of gene 
therapy.  
 
Mutations of RPE65, which encodes retinoid isomerohydrolase, result in retinitis 
pigmentosa 20 (RP20) and LCA, type 2, a subtype of LCA that has been extensively 
evaluated in preclinical animal models. Gene-replacement therapy, through subretinal 
delivery of recombinant AAV vectors containing RPE65 cDNA, has been shown to 
improve electrophysiological responses and functional vision in the Swedish Briard dog, 
a naturally occurring animal model with mutated RPE65 (25-26). The success of the 
preclinical murine and large-animal models translated into a number of human trials 
evaluating the safety of injecting AAV vectors containing the human RPE65 coding 
sequence (26). All of the studies reviewed below, have similar outcomes, but vary 
slightly in their designs with respect to the use of specific promoters for enhancing the 
expression of RPE65, the volume of vector injected, and the surgical protocol for vector 
delivery.  
 
Three small phase I studies were published in 2008 and are summarized in Table 1 (27-
29). In these studies, adverse events were related to the surgical procedure and there were 
preliminary signals of efficacy. Major similarities in methods between studies included 
the utilization of a PPV with subretinal vector delivery. The favorable safety profile and 
possible effectiveness of these pilot studies led Maguire et al. to perform a dose-
escalation phase I study of 12 patients age 8-44 years (NCT00516477) (30). Patients were 
randomized to receive a low dose (1.5 x1010 vector genomes (vg) in 0.15 mL), a medium 
dose (4.8 x1010 vg in 0.15 mL), or a high dose (1.5x1011 vg in 0.3 mL) subretinally 
following PPV. They reported AAV2-hRPE65v2 vector was well tolerated, and all 
patients showed sustained improvement in subjective and objective measurements, 
including pupillometry, VA, visual field testing, nystagmus, and ambulatory behavior. 
(30). The same group reported that visual function improvements remained stable up to 3 
years (31).  Alternatively, Jacobson et al. and Bainbridge et al. reported less promising 
long-term outcomes; direct comparison between these groups is difficult, however, as 
they used different virus vectors, manufacturing processes, and lower doses (32-33). 
 
Given the favorable results from the phase 1 trial reported by Maguire et al., Spark 
therapeutics is sponsoring commercialization of this therapy in their lead ocular program. 
The evaluation of RPE65 gene (AAV2-hRPE65v2) administered to the contralateral eye 
in patients enrolled in the phase 1 study was recently released (NCT01208389) (34). 
Since there were no dose-limiting toxicities in the first study, the highest dose of 1.5x1011 
vg in 0.3 mL was subretinally injected into the contralateral, previously uninjected, eyes 
in 11 of the 12 patients. Although there was theoretical concern surrounding the possible 
increased risk of an immune response due to the previously introduced AAV2 vector, 
most patients did not experience significant immunogenicity. Obstacles for evaluating 
visual function with VA testing after genetic treatment may be limited by developmental 
deficiencies in the visual cortex in individuals with poor vision since birth. In addition to 
amblyopia, other obstacles include limited dynamic range of VA testing, and the fact that 
LCA and RP are predominantly rod-mediated disorders with secondary effects on cone 
function and VA, decreasing its sensitivity to change in visual function. To more fully 
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assess the functional benefits of RPE65 gene therapy in LCA patients, who do not 
perform well on traditional methods of vision testing, a proprietary multiluminace 
mobility test (MLMT) was developed, with feedback from the FDA in order to 
functionally assess VA, visual fields, light sensitivity, and mobility.  In this test, patients 
progress through an “obstacle course”, with 12 standardized templates, under multiple 
standardized lighting conditions, to determine the lowest illumination under which they 
can successfully navigate the course in under 3 minutes.  The seven levels of illumination 
reproduce the lighting conditions encountered in daily life, from 1 lux, simulating a 
moonless night, to 400 lux, simulating an office setting.  A change in score, based on 
illumination level, functions as the endpoint and has been validated.  Compared with 
baseline, of ten participants analyzed, improvements in MLMT and full-field light 
sensitivity testing (FST) in the injected eye by day 30 persisted to year 3 (MLMT 
p=0.0003, FST  p<0.0001), and no significant change was seen in the previously injected 
eyes or VA assessments over the same time period (34). 
 
According to publicly disclosed information, Spark initiated a Phase III trial in November 
2012 enrolling 31 patients with a mean age of 15 years; the patients were randomized 2:1 
into control or receiving 1.5 x 1011 vg of SPK-RPE65 in both eyes within 18 days. After 
the 12-month time point, the control subjects were eligible to cross over into the 
treatment group. In October 2015, Spark announced positive top-line results.  There were 
no serious adverse events (SAEs) or significant immune responses related to SPK-
RPE65.  The trial met its primary endpoint of change at one year in the bilateral MLMT 
from baseline (p=0.001), with an average improvement 1.8 light levels in the treatment 
group versus 0.2 light levels in the control group. Of the 20 treated subjects, 13 (65%) 
were able to pass the MLMT at the lowest light level (1 lux, demonstrating maximal 
possible improvement) at one year versus none in the control group.  Secondary 
endpoints successfully met included FST with 100-fold improvement in light sensitivity 
in treated subjects (p<0.001) and MLMT change score for the first injected eye 
(p=0.001).  Although the VA secondary endpoint did not reach statistical significance, a 
beneficial trend was noted among treated patients (35).  In May 2017, Spark announced 
that it had completed its rolling Biologics License Application (BLA) submission to the 
FDA for SPK-RPE65, Voretigene Neparvovec, which could potentially represent the first 
approved genetic therapy in the United States (36). 
 
In addition, alternative vectors such as AAV4-RPE65 have been evaluated for RPE65 
specific retinal dystrophies (NCT01496040) (37). Other companies that are sponsoring 
gene therapy trials for LCA include Applied Genetics Technology Corporation (AGTC) 
(38) and MeiraGTx.  MeiraGTx has initiated a phase I/II clinical trial of AAV-
OPTRPE65 (39). 
 
In addition to RPE65, a mutation in GUCY2D has been implicated in LCA type 1. 
GUCY2D encodes retinal guanylyl cyclase-1, a protein expressed in the outer 
photoreceptors that responds to low intracellular calcium levels and produces cGMP to 
return the photoreceptors to the pre-excitation state after light exposure (40-41). A 
mutation in GUCY2D caused decreased VA and ERG dysfunction, but unlike LCA2 
patients often have normal laminar structures of the retina (40). A mouse model was 
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recently rescued with an AAV5-GRK1-GUCY2D delivered gene replacement and the 
results found a restoration of retinal function for 6 months (40). There are no clinical 
trials to date for GUCY2D mutations, but these animal model findings indicate that 
patients with this mutation may benefit from future gene therapy.  
 
Finally, the retinitis pigmentosa GTPase regulator protein (RPGRIP1) gene encodes a 
structural protein that localizes to the connecting cilium linking the inner to the outer 
segment and is involved in the regulation of protein trafficking across the cilium (19). 
Loss of this gene has been implicated in photoreceptor degeneration and LCA 
development. The RPGRIP1−/− knockout mouse develops a severe retinal degeneration. 
AAV2 constructs with an opsin promoter and murine RGRIP1 cDNA were injected 
subretinally into the knockout mouse model. Treated eyes were found to have 
photoreceptor structural preservation as determined by a thicker and well-developed outer 
nuclear layer on histologic examination. Additionally, the RPGRIP restored normal 
subcellular localization of the RPGR. ERG b-waves declined by 22% per month in the 
untreated eyes, while the treated eyes declined by 6% per month. Five months post 
injection, the mean b-wave amplitudes in the treated eyes were significantly higher than 
the b-wave amplitudes in control eyes. (42)  
 
2.2 Gene therapies for Choroideremia: 
Choroideremia is an X-linked chorioretinal dystrophy characterized by diffuse, 
progressive degeneration of the RPE, photoreceptors and choriocapillaris. It has a 
prevalence of about 1 in 50,000 with northern Finland having the highest reported rate 
(43). The disease is characterized by progressive vision loss, but unlike LCA, central 
vision is maintained until the fourth or fifth decade of life and males are predominantly 
affected due to its X-linked inheritance pattern. It is caused by a mutation in the CHM 
gene, which encodes for Rab escort protein-1 (REP-1) and is the focus of ongoing gene 
replacement therapy. REP-1 is a ubiquitously expressed protein required for the efficient 
geranylgeranylation prenylation, (a post-translational modification of proteins involving 
the attachment of geranylgeranyl isoprene units) of ras-related GTPases, or Rab proteins, 
which are integral to the trafficking of vesicles in endocytic and exocytic pathways (44-
46). It has been suggested that this lack of protein affects opsin transport to photoreceptor 
outer segments, apical migration of RPE melanosomes, and the phagocytosis of 
photoreceptor outer segments by the RPE resulting in progressive RPE and photoreceptor 
cell death (47). 
 
Recent success in the treatment of LCA, as reviewed above, has brought about the 
evaluation of AAV vector-mediated gene replacement in choroideremia. The cloning 
capacity of AAV vectors is approximately 4.5-5.0 kb, which is greater than the 
approximately 1.9 kb coding sequence of REP-1, making it an excellent vector for 
delivery (48-50).  The replacement of the REP-1 gene was evaluated in a choroideremia 
murine model, in which mice were designed to have an REP-1 deficiency. In this 
preclinical model, REP-1 replacement via the subretinally injected AAV2 vector was 
demonstrated to be feasible, safe, and improved ERG responses (51).  
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This proof-of-concept study led to a human multicenter phase 1/2 clinical trial, in which 
six male patients (aged 35-63 years) were administered with AAV.REP1 
(NCT01461213). The surgical technique involved PPV followed by placement of 0.1mL 
of 1×1010 AAV2.REP1 genome particles into the subretinal space in 5 of 6 patients. In 
the sixth patient, a reduced dose of 0.1 mL of 6×109 was injected. The sixth patient was 
injected with a smaller dose of viral particles because of difficulty in creating a retinal 
bleb and concern about stretching the papillomacular bundle. VA was measured using the 
Early Treatment Diabetic Retinopathy Study (ETDRS) letters, which requires a change of 
at least 0.2 logMAR (2 lines of letters) to distinguish from no change (52). At six months, 
the mean ETDRS letters was +3.8 letters in the treated eyes in comparison to +1.5 letters 
in the control eyes, although statistical analysis was not published due to the small 
sample size. Patient 1 had a +21 letter improvement and patient 4 had a +11 letter 
improvement, with the other patients having a marginal loss in VA. On microperimetry, a 
mean increase was noted in retinal sensitivity with respect to the dimmest stimulus seen 
(2.3 dB), with respect to mean retinal sensitivity (1.7 dB) and with respect to total 
number of test points seen (1.5), in contrast to a reduction in all of these parameters in the 
patient's contralateral eye. Mean retinal sensitivity increased by 2.5 dB in the five eyes 
administered with the full dose of vector, but fell by 2.3 dB in the eye administered with 
the reduced dose. There was no observed immune response to the injected viral particles. 
Two patients had mild distortion of central vision, which resolved by 6 months. All 
patients had sub-clinical progression of lens opacification, as expected following PPV. 
No serious systemic or ocular adverse events were reported. Importantly, no retinal 
thinning or loss of VA was observed despite the surgically induced retinal detachment, 
establishing a favorable safety profile for this gene transfer protocol targeting the fovea. 
Interestingly, one patient demonstrated a shift in the preferred retinal locus from the 
fovea to the area adjacent to the site of vector treatment (44).  
 
At 3.5 years, the patients who had initial improvement in VA maintained that VA. Three 
other patients did not have a significant change in VA and one patient had a decline in 
vision. The patient who had a decline in vision was the patient injected with a lower total 
vector dose (53).  Based on this work from the University of Oxford, NightstaRx is 
sponsoring additional clinical trials with NSR AAV-REP1, which is expected to enter 
Phase 3 pivotal testing, pending final discussions with the FDA (54). 
 
Spark Therapeutics has also sponsored an open-label, dose-escalating Phase 1/2 trial 
designed to assess the safety and preliminary efficacy of subretinal administration of 
investigational SPK-7001 in choroideremia. The trial enrolled 2 dose cohorts of 5 
patients with advanced disease and initial efficacy analysis is expected in 2017 (55). 
  
The pathogenesis of choroideremia is complex and it is thought to affect RPE, 
photoreceptors, and choroid, but which retinal layer is affected most in this disease has 
yet to be determined (46). Some studies have demonstrated that both RPE and 
photoreceptors are affected in CHM and that an affected RPE accelerates photoreceptor 
degeneration, highlighting RPE as the primary layer affected in CHM (56). Other studies 
have suggested that rod cell death results in secondary cone mediated death and is the 
primary site of CHM pathology (57). However, REP-1 was also localized to cone 
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photoreceptors, raising the question as to whether rods and cones need to be 
independently targeted with vector therapy (58).  This has led to the investigation of other 
vectors such as AAV8 that are being explored because of the increased tropism for 
photoreceptors when compared with the AAV2 vector. Preclinical in vitro and in vivo 
murine studies demonstrated successful dose responsive expression of REP-1 in 
photoreceptors using an AAV8 vector (59-60). The AAV2 viral vector was designed to 
target RPE cells and it is hypothesized that the use of a viral vector such as AAV8 that 
targets both RPE and photoreceptors may increase therapeutic efficacy and decrease the 
dosage required. Further advancements in CHM research has been limited by this 
complex pathophysiology and existing animal models that do not replicate the human 
condition (46). With better understanding of the pathology of CHM, clinical research 
developing an accurate animal model is being investigated as a way to contribute to 
innovative therapeutic approaches (46). 
 
2.3 Gene therapies for Retinitis Pigmentosa (RP):  
Retinitis pigmentosa is a heterogenous hereditary disorder resulting in diffuse, 
progressive photoreceptor loss preferentially affecting rod photoreceptors with secondary 
loss of cones. Epidemiologic studies vary by population, but RP is the most frequent form 
of inherited retinal dystrophies with a prevalence of 1 in 4,000 cases worldwide (61). 
Patients classically present with nyctalopia early in the course of disease, progressive loss 
of peripheral vision and eventually develop central visual impairment. On fundus 
examination, patients have arteriolar narrowing, bone spicule-like pigmentary changes 
and waxy pallor of the optic disc. A mutation in RHO, which encodes rhodopsin, was the 
first one associated with the disease, but numerous other genetic mutations have 
subsequently been identified, including genes encoding for mer receptor tyrosine kinase 
(MERTK), usherin, as well as retinitis pigmentosa GTPase regulator (RPGR) and 
retinoid isomerohydrolase (encoded by the RPE65 gene).  As described above, these 
latter two mutations overlap in LCA, demonstrating the limited utility of the original 
phenotypic diagnoses in an era in which genotyping becomes more widely adopted.  
 
MERTK encodes a tyrosine kinase that is required for phagocytosis of photoreceptor 
outer segments by the RPE and is associated with a rare form of autosomal recessive RP 
(62-64). The genetic mutation and its resultant pathology has been extensively studied in 
preclinical models mainly because it is the gene mutation in Royal College of Surgeon 
(RCS) rats, a popular model for retinal dystrophies, including RP (64). Several studies 
successfully treated RCS rats with the AAV2 vector carrying the MERTK gene and 
further improved the therapy through use of the RPE-specific promoter, vitelliform 
macular dystrophy (VMD2) (65-67). A phase I clinical trial sponsored by Fowzan 
Alkuraya (NCT01482195) utilizing an AAV2 vector with an RPE-specific promoter 
(VMD2) driving MERTK was published in 2016. To date, six patients received a 
submacular injection of AAV2-VMD2-hMERTK. One eye of each patient received a 
nonfoveal, submacular injection of the viral vector, with the first two patients receiving a 
dose of 0.15 ml (5.96 × 1010vg) and the four other patients receiving 0.45 ml (17.88 × 
1010vg).  Postoperatively, one patient retained the subretinal bleb for a much longer than 
expected period of time (>3 weeks) and experienced “vibratory movement of the object.”  
It was not clear to the authors if this was related to the bleb and neurophthalmic 
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evaluation did not reveal an ocular movement disorder. Of note, two patients 
demonstrated an increased AAV antibody serum titer following the injection, but neither 
patient was positive for rAAV vector genomes using PCR. The clinical implication of 
this rise, as in the previously discussed sections, is not entirely clear, but the authors 
suspected the antibody detection to be cross-reactivity as opposed to true systemic viral 
exposure. No systemic complications attributed to the vector were observed. Three 
patients displayed improved VA in the treated eye at follow-up visits. However, this 
improvement in VA declined to baseline 2 years post treatment in two of the patients and 
only one patient demonstrated a sustained improvement in VA from baseline of 20/200 to 
20/80 at 2 years (68). 
 
The retinitis pigmentosa GTPase regulator (RPGR) gene is involved in 70% of X-linked 
RP and up to 20% of all RP cases. RPGR encodes for a transporter protein in the cilium, 
connecting the inner and outer segments of photoreceptors and suspected to play a role in 
transporting phototransduction components across the connecting cilium.  X-linked RP 
due to RPGR mutations carries a poor prognosis associated with an aggressive course. 
AAV subretinal delivery of RPGR-ORF15 in an RPGR null murine model was found to 
have appropriate localization of transgene expression to the connecting cilium with 
structural and functional photoreceptor rescue (69).  Additionally, subretinal AAV 2/5 
RPGR was injected into canine models and demonstrated preserved photoreceptor 
morphology and improved rod and cone function (70). In March of 2017, NightstaRx 
announced that it has initiated a Phase I/II clinical trial (NCT03116113) of subretinal 
injection of AAV-XLRPRG gene therapy for X-linked RP caused by RPRG mutation.  
The clinical trial is an open-label dose escalation study with planned enrollment of 24 
patients (54).  MeiraGTx is also developing a gene therapy to target the RPGR gene in 
photoreceptor cells, but has not initiated clinical trials (39). 
 
Unlike autosomal recessive or X-linked RP, a challenge in treating dominant RP (a 
significant proportion of RP cases) relates to the need to inhibit a gene, which can result 
in untoward effects on cellular physiology due to a narrow window of gene expression 
required for proper cellular function. To address this, Farrar et al. reviewed the different 
methods that are being developed to supplement normal gene expression while at the 
same time inhibiting the expression of the mutated gene (71). Another hurdle is that 
rhodopsin (RHO)-linked autosomal dominant RP (~25% of autosomal dominant RP) is 
caused by over 150 different mutations in the RHO gene alone, and the time and cost of 
developing sequence-specific inhibitors for each mutation is not economically feasible 
(72). Finally, most previously studied viral vectors were designed to target RPE cells, 
with minimal tropism for photoreceptors.  Several alternative viral vectors, including 
AAV2/5, AAV2/8 and AAV2/rh10 have been designed and found to be tropic to 
photoreceptors and to be effective for gene transfer in animal models. However, they 
have not been evaluated for safety and efficacy in humans to date (72-73). 
 
2.4 Gene therapies for Usher Syndrome: 
Usher syndrome is an autosomal recessive genetic disease caused by a number of genetic 
mutations.  One of the most investigated genes is Myocin VIIA and mutation in this gene 
is characterized by retinitis pigmentosa and progressive hearing loss with possible 
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vestibular dysfunction (74). The prevalence of Usher syndrome has been reported to 
range from 3.2 to 6.2 per 100,000 (75). Myocin VIIA (MYO7A) is expressed in cochlear 
hair cells of the inner ear as well as in retinal photoreceptors and the RPE, where it plays 
a role in multiple cellular processes, including endocytosis and opsin delivery (76). 
Although the amount of MYO7A in photoreceptors is lower than that in the RPE, 
photoreceptors are affected before RPE cells in patients with Usher1B, indicating that 
photoreceptors are important cells to target in this disease.  
Due to the large size of the MYO7A cDNA, delivery methods other than AAV are being 
investigated. The ability of lentivirus-MYO7A to restore RPE abnormalities has been 
shown in the MYO7A knockout mouse after subretinal injection of the vector at birth (77). 
Subretinal injections of EIAV-CMV-MYO7A (UshStat) in the mouse model of USH1B 
decreased the amount of photoreceptor loss and restored the transducing translocation in 
photoreceptors (77). In 2009, Oxford Biomedica entered into collaboration with Sanofi-
Aventis to investigate the utilization of the lentivirus gene delivery system for treating 
ocular diseases such as Usher syndrome type 1B and Stargardt disease (78). Currently 
patients with USH1B are being recruited for a phase I/II trial to assess the safety and 
tolerability of subretinal EIAV-CMV-MYO7A. 
In addition to lentivirus, other delivery methods are being investigated. Specifically, 
DNA-compacted nanoparticles, which are single DNA molecules compacted 
polyethylene glycol-substituted polylysine 30-mers (CK30PEG). These have a 20 kb 
packaging capacity, providing future possibilities for gene therapy, with particular utility 
in treatment of Usher 2A syndrome, associated with mutations in the Usherin gene – a 
15.6 kb sized gene that prohibits packaging into any AAV vectors (79). The safety and 
utility of the nanoparticles has been demonstrated in the lung, with introduction of the 
cystic fibrosis transmembrane conductance regulator through an intranasal route (80). 
However, nanoparticles have shown some limitations hindering their widespread use in 
ocular gene therapy. It was found to have lower transduction efficiency per vector 
genome as compared to AAV. This would require higher vector amounts and repeated 
dosing schedules, which could be dangerous in subretinal injections for ocular disease 
(81). 
 
2.5 Gene therapies for Stargardt Disease: 
Stargardt disease is a juvenile inherited macular dystrophy caused by a mutation in the 
ATP binding cassette subfamily A member 4 (ABCA4) gene with an estimated 
prevalence of between 1 in 8,000 to 10,000 (82). Subtle symptoms typically present 
during childhood followed by progressive macular atrophy, which ultimately results in 
severe vision loss in young adults. ABCA4 is localized to the outer segments of 
photoreceptors and acts as a membrane transporter for the recycling of a chromophore 
during the visual cycle. Specifically, ABCA4 binds with high affinity and shuttles N-
retinylidene-phosphatidylethanolamine trapped inside the photoreceptor disc across the 
membrane surface, where it is ultimately further processed by the adjacent RPE cells as 
part of the visual cycle.  Loss of ABCA4 function is associated with accumulation of 
toxic N-retinylidene-N-retinylethanolamine (A2E) in RPE cells, followed by severe RPE 
and macular photoreceptor death (83-84). The accumulation of this lipofuscin-like 
material results in the classical dark choroid found on fluorescein angiography. The 
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ABCA4 gene (6.8 kb) exceeds the 4.5-5.0 kb capacity of the AAV vector and has 
required utilization of vectors such as the equine infectious anemia lentivirus (EIAV) for 
gene transfer (85). Subretinal injection of EIAV-ABCA4 was found to be effective in a 
knock out mouse model.  Currently, Oxford Biomedica in coordination with Sanofi, is 
sponsoring an escalating dose Phase I/II EIAV-ABCA4 clinical trial investigating its 
utility in Stargardt disease (86-88). 
 
2.6 Gene therapies for Leber’s Hereditary Optic Neuropathy (LHON): 
LHON is an inherited mitochondrial optic neuropathy with progressive optic atrophy 
from retinal ganglion cell death with an associated central visual field defect, decreased 
color vision and reduced contrast sensitivity. Prevalence of the disease is not well known 
but is estimated at 1 in 8,500-50,000 people worldwide (89). The most common 
mutations identified in mitochondrial genes include ND1 (G3460A), ND4 (G11778A), 
and ND6 (T14484C). These genes encode complex I (NADH dehydrogenase) of the 
electron transport chain necessary for mitochondrial energy production and cellular 
function (90). A G-to-A transition in mitochondrial DNA at position 11778 in the gene 
encoding subunit 4 of NADH dehydrogenase (ND4) leads to a position 340 arginine-to-
histidine substitution that is responsible for approximately half of LHON cases.  
Investigations into genetic therapy have been limited by the difficulty with delivering 
genes into the mitochondria of the ganglion cells. A strategy that has proved successful is 
allotopic expression (i.e. expression of the mitochondrial gene in the nucleus), optimized 
to target the mRNA to the outer surface of mitochondria. This facilitates translocation of 
the translated protein into mitochondria (91). Qi et al. showed that this approach would 
create the LHON phenotype in a normal mouse by delivering mutant 11778 human ND4 
cDNA in an AAV2 vector to the mitochondria of retinal ganglion cells (92). This same 
technique was found to rescue a LHON rat model with intravitreal delivery of ND4 
utilizing an AAV vector (93).  
 
Currently, clinical trials are attempting to utilize allotopic expression to deliver ND4 in 
ganglion cells in patients with LHON G11778A mutations. Feuer et al. published the 
preliminary results for five patients that had been investigated following intravitreal 
injection of self-complementary AAV [scAAV]2(Y444,500,730F)-P1ND4v2. The first 3 
participants were treated at the low dose of vector (5x109 vg), and the fourth participant 
was treated at the medium dose (2.46x1010 vg). The fifth participant with visual loss for 
less than 12 months received the low dose. They reported no serious safety issues. An 
increase in VA was observed in two of the patients after gene delivery (NCT02161380) 
(94). However, the study design and outcomes reported in the paper have recently been 
called into question by some authors, with concerns about bias in the variable choice of 
baseline visit dates chosen for comparison, the likelihood of placebo effect due to one of 
the patients noticing an improvement on the first postoperative day and the possibility of 
spontaneous improvement of symptoms as part of the natural history of the disease in 
some patients (95). 
 
Separately, Wan et al. released a report regarding a completed study from China that 
utilized a recombinant AAV2 carrying ND4 injected intravitreally in nine recruited 
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patients (NCT01267422). These patients were followed over nine months and key 
findings included lack of systemic or ocular adverse events related to the vector, six of 
the nine patients measured a 0.3 log MAR improvement in VA and these six patients had 
an associated visual field enlargement (96). 
 
GenSight Biologics is sponsoring two phase 3 randomized double-masked sham-
controlled clinical trials (“RESCUE” and “REVERSE”) of their GS010, AAV-mediated 
therapy containing the ND4 gene, for the treatment of LHON.  The trials are to enroll 36 
patients each and the first patient was recruited in February 2016, with the final patient to 
be enrolled expected in 2017.  The primary endpoint is mean difference in BCVA in 
treated patients compared to sham patients.  Topline results are expected at the end of the 
first quarter 2018 (97). 
 
2.7 Gene therapies for Achromatopsia: 
Achromatopsia (ACHM, rod monochromatism) is an autosomal recessive retinal 
condition that presents early in life with poor VA and color vision, photophobia, and 
nystagmus secondary to the absence of cone photoreceptors (98). It affects approximately 
1 in 33,000 people in the US.  Currently, six genes 
(ATF6, CNGA3, CNGB3, GNAT2, PDE6C and PDE6H) have been linked to ACHM. 
Approximately 50% carry mutations in the CNGB3 and 25% carry mutations in the 
CNGA3 gene, which encode the two subunits of the cone cyclic nucleotide-gated (CNG) 
channel respectively (99). Other cases are associated with guanine nucleotide-binding 
protein G subunit alpha-2 (GNAT2) and phosphodiesterase 6C and 6H (PDE6C, 
PDE6H).  All of these proteins play a critical role in cone phototransduction and their 
deficiency or malfunction results in retinal cone pathology (100). Mouse, canine, and 
sheep models have demonstrated the ability to replace these particular genes (101-103).  
 
STZ eyetrial is sponsoring a dose escalation safety and efficacy phase I/II trial utilizing a 
single subretinal injection of rAAV.hCNGA3 for patients with CNGA3-linked 
achromatopsia (NCT02610582). MeiraGTx is also sponsoring a phase I/II trial to 
evaluate the safety for AAV-mediated CNGB3 delivery to patients with congenital 
ACHM and the company plans to initiate a similar phase I/II trial of AAV-mediated 
delivery of CNGA3 (NCT03001310).  Applied Genetic Technologies Corporation 
(AGTC) is currently recruiting individuals with CNGB3 mutations into a phase I/II 
clinical trial to receive a subretinal injection of AAV expressing CNGB3 (rAAV2tYF-
PR1.7-hCNGB3) (NCT02599922), and is also sponsoring a dose escalation phase I/II 
clinical trial of AAV-mediated CNGA3 gene therapy in ACHM, with planned doses of 
1.8 x 1011 vg, 4.5 x 10 11 vg, and 1.35 x 1012 vg, and a primary endpoint of safety as well 
as secondary endpoints of VA and color vision (NCT02935517) (104).  
 
2.8 Gene therapies for X-Linked Retinoschisis (XLRS): 
XLRS is characterized by splitting of the retinal layers and the presence of intraretinal 
fluid-filled cysts, which results in a variable degree of visual dysfunction in young males. 
This separation leads to a characteristic decrease in the ERG b-wave with preservation of 
the a-wave secondary to the poor synaptic transmission between the photoreceptors and 
bipolar cells, resulting in the “negative ERG” (105). Estimates of the prevalence of X-
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linked retinoschisis vary from 1 in 5,000 to 1 in 25,000 (106). A mutation in retinoschisin 
(RS1), which plays a role in retinal organization and synapse structure, accounts for these 
findings. The absence of RS1 in the mouse model demonstrated similar findings to 
retinoschisis with fluid filled cavities and progressive photoreceptor cell death (107). 
Gene therapy has been underway to target this mutation in animal models (108). Unique 
to this condition, because of the weakness of the retina in retinoschisis, an approach with 
an intravitreal injection is favored over a subretinal approach (109). An AAV8-mediated 
delivery of RS1 induced reorganization of the photoreceptor and bipolar cell synapses 
with restoration of function in the RS1 knockout mouse model (110-111). This prompted 
the initiation of two clinical trials investigating the intravitreal delivery of AAV-RS1 
vector in those affected by XLRS.   AGTC is sponsoring a dose escalation phase I/II 
clinical trial of AAV-mediated RS1 gene therapy in XLRS, their lead program.   Dosing 
will include 1x1011 vg, 3x1011 vg, and 6x1011 vg, with a primary endpoint of safety as 
well as secondary and supportive endpoints of VA, visual fields and ERG 
(NCT02416622) (112).  The National Eye Institute is conducting an open-label of an 
AAV8-mediated RS1 gene therapy in XLRS (NCT02317887). 
 
CONCLUSION: 
The evolution of gene therapy has been remarkable over the last decade and has proven 
to be relatively safe in a multitude of small clinical trials, albeit with varying outcomes. 
With the optimization of viral vector transduction, improvements in cell-specific tropism, 
improved transgene expression through gene promoters, utilization of additional vectors 
with larger gene capacities, and advances in the surgical delivery of genetic treatments, 
the future of gene therapy shows great promise (113-114). Additionally, better 
understanding of the pathophysiology of retinopathies as well as the mechanisms that 
limit gene replacement therapy will facilitate further refinement of gene therapy for 
retinal degenerations.  
 
EXPERT OPINION:  
To date there is no approved treatment for the stabilization or reversal of vision loss in 
patients with IRDs. The rarity of these diseases limit large scale clinical trials.  However, 
the partnership of industry sponsors with basic science researchers, incentivized by the 
Orphan Drug Act, have created a supportive environment for gene therapy in IRDs. 
 
Gene therapy has an acceptable safety profile in many of the clinical trials, with low risk 
of local immunogenic response and no evidence of significant systemic adverse events. 
However, efficacy remains uncertain and variability exists in visual outcomes between 
disease processes, method of gene therapy and outcomes measured. In particular, 
traditional clinical trial endpoints involving VA, with its limited dynamic range and its 
predominant relationship to cone function, are problematic in advanced rod-mediated 
retinal degenerative disease or in children with dense amblyopia; consequently, 
alternative clinical trial endpoints have been developed.  For instance, the results of the 
most recent LCA Phase 3 trials demonstrated an improvement in MLMT and FST, but 
the trend in improved VA did not reach statistical significance. However, MLMT may 
more comprehensively assess vision as it more functionally assesses VA, visual fields, 
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light sensitivity, and mobility in these patients. Furthermore, these novel study endpoints 
are clinically meaningful to regulators. 
 
In addition to efficacy endpoints, many issues and questions remain. For instance, even 
the nomenclature of various IRDs may require further development, given the overlap 
and variation among phenotypic diagnoses, in an era in which genotyping becomes more 
widely adopted, and gene-specific therapies are ultimately implemented.  In addition, the 
safest and most effective approach for delivering the viral vector is unclear, especially as 
vector technology evolves.  In order to minimize surgical complications, intravitreal 
delivery has been evaluated in XLRS and LHON, but this approach has the potential for 
lower penetration to the deeper retinal tissues, which are the main targets in many of the 
IRDs. Subretinal delivery likely fosters greater transduction over intravitreal delivery, but 
risks surgical complications during vector administration. Also, the longevity of gene 
expression from a one-time delivery of a vector genome is unknown and it is unclear if 
the eye can tolerate additional treatments to enhance cellular gene expression.  Finally, 
adoption of gene therapy for IRDs will require widespread genetic screening to identify 
patients based on genotype, as well as new reimbursement models for one-time therapies. 
 
In summary, gene therapy for IRDs is still in its early stages but holds great promise 
when treating monogenic IRDs, especially given the improvements in viral vector safety, 




• Gene therapy has a promising future in the treatment of degenerative retinal 
diseases. 
• A variety of viral vectors and surgical delivery techniques are being investigated 
in clinical trials to identify the safest and most effective method for targeting 
pertinent retinal cellular structures.  
• Local tolerability of vector therapy for IRDs has been demonstrated in numerous 
small studies and no serious systemic complications have been reported.  
• Continued advancements in the understanding of the pathophysiology of IRDs 
will allow for improved, more targeted, genetic therapy.  
• The monogenic nature of IRDs and lack of effective treatment to date makes gene 






























Table 1. Comparison of phase 1 Leber’s Congenital Amaurosis safety report studies 
 
Table 2: Ongoing or recently completed human gene therapy trials for inherited 




Figure 1: Subretinal injection: This figure demonstrates the location of a subretinal 
injection of therapeutic viral vectors, a procedure that is performed in an outpatient 
surgical setting.  After pars plana vitrectomy to remove vitreous, a small retinotomy 
is created and the neurosensory retina is detached to create a small bleb. The 
vectors are then delivered directly into this iatrogenic space, between the 
photoreceptors and the retinal pigment epithelium. The volume and dose of viral 
vector, precise retinal location within the eye, and the number of retinotomies 
through which to deliver has yet to be been optimized. Reproduced figure with 
permission from Expert Opinion on Biological Therapy: Gene therapy for age-
related macular degeneration DOI: 10.1080/14712598.2017.1356817. 
 
Figure 2: Intravitreal injection: This figure represents the location of an intravitreal 
injection of therapeutic viral vectors, a brief office-based procedure.  Following 
local anesthesia and application of betadine to reduce the risk of infection, a small-
gauge needle is inserted through the pars plana into the vitreous. The vector is 
injected directly into the vitreous humor and must traverse posteriorly through the 
vitreous and inner retinal layers in order to transduce the retinal pigment 
epithelium and photoreceptors. Reproduced figure with permission from Expert 
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